Liquidia Corporation Reports Second Quarter 2024 Financial Results and Provides Corporate Update
07. August 2024 06:30 ET
|
Liquidia Corporation
Liquidia Corporation (NASDAQ: LQDA) today reported financial results for the second quarter ended June 30, 2024.
District Court Issues Favorable Ruling and Denies United Therapeutics’ Request to Block YUTREPIA™ Launch
03. Juni 2024 07:00 ET
|
Liquidia Corporation
Judge Andrews denied the motion for preliminary injunction filed by United Therapeutics that sought to block the launch of Liquidia’s YUTREPIA™.
Global Medical Inhaled Nitric Oxide Market Growth Projection: Aiming for USD 1,520 Million by 2030 with a 7.7% CAGR
18. September 2023 07:24 ET
|
Zion Market Research
Washington, DC, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Zion Market Research has published a new research report titled “Medical Inhaled Nitric Oxide Market By Product Type (Inhaled Nitric Oxide Delivery...
Cardiotonic Agents Market Size to Reach USD 4.5 Bn by 2031 Due to the Rise in Prevalence of Cardiovascular Diseases | TMR Study
03. April 2023 11:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, April 03, 2023 (GLOBE NEWSWIRE) -- According to the market study by Transparency Market Research, the global cardiotonic agents market was worth USD 732 Million...
Inhaled Nitric Oxide Market Size is projected to reach USD 1.54 Billion by 2030, growing at a CAGR of 8.4%: Straits Research
11. August 2022 16:00 ET
|
Straits Research
New York, United States, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Inhaled nitric oxide is a pulmonary vasodilator that considerably controls vascular muscle tone. It has emerged as a therapy for hypoxemic...
Pulmonary Hypertension Clinical Trials Pipeline Offers Promising Novel Treatment Options | DelveInsight
01. August 2022 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Pulmonary Hypertension Clinical Trials Pipeline Offers Promising Novel Treatment Options | DelveInsight DelveInsight’s pulmonary hypertension...
Ferrer Announces Distribution Agreement With United Therapeutics for Treprostinil Inhalation Solution for Pulmonary Hypertension Associated With Interstitial Lung Disease
28. Februar 2022 06:00 ET
|
Ferrer
BARCELONA, Spain, Feb. 28, 2022 (GLOBE NEWSWIRE) -- In the run up to Rare Disease Day, which is held on 28 February, International pharmaceutical company Ferrer has strengthened its focus on...
Halo Biosciences Participating in BIO @ JPM and BIOTECH SHOWCASE™ During J.P. Morgan Week 2022
10. Januar 2022 08:00 ET
|
Halo Biosciences
SAN FRANCISCO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Halo Biosciences, a clinical stage biopharmaceutical company today announced that its Chief Executive Officer, Anissa Kalinowski, MSc, MBA, will...
Nu-Med Plus Closely Monitoring Outcomes on Two New Human Clinical Trials Using Inhaled Nitric Oxide in Treatment of COVID-19
25. März 2020 06:00 ET
|
Nu-Med Plus Inc.
SALT LAKE CITY, March 25, 2020 (GLOBE NEWSWIRE) -- Nu-Med Plus, Inc. (OTCQB: NUMD), a medical device company which investigates and develops applications and devices for nitric oxide in the medical...
38th Annual International Society for Heart and Lung Transplantation (ISHLT) Annual Meeting & Scientific Sessions Kicks Off with the INTERHEART Study, Pulmonary Hypertension and Heart Attack Recovery Using LVADs
11. April 2018 06:50 ET
|
International Society for Heart & Lung Transplantation
NICE, France, April 11, 2018 (GLOBE NEWSWIRE) -- Researchers at the Alberta Transplant Applied Genomics Centre (ATAGC) at the University of Alberta in Edmonton, Canada presented results of The...